ArticleCancer discovery2017
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers.
0numbers the graph read from it
0cells of the map it votes in
233citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
233 citing papers in PubMed, 320 citations in OpenAlex.
- MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma.Molecular cancer research : MCR · 2026Article
- Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.British journal of cancer · 2026Review
- PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells.Cancers · 2026Article
- Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers.Cell reports. Medicine · 2026Article
- CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.Cancer discovery · 2026Article
- Article
- Core transcriptional regulatory circuitry identified from patient-derived tumor cells provides a specific vulnerability for rhabdomyosarcoma.Cell death & disease · 2026Article
- Article
- Fusion-positive rhabdomyosarcoma oncofusions share a common interactome.Nature communications · 2026Article
- Dual inhibition of KDM4B and KDM5A disassembles the PAX3-FOXO1 transcriptional program in fusion-positive rhabdomyosarcoma.Biology direct · 2026Article
- Targeting fusion proteins in solid tumors: from oncogenic mechanisms to clinical interventions.Acta pharmacologica Sinica · 2026Review
- HES3-dependent regulatory functions in development and fusion-positive rhabdomyosarcoma.bioRxiv : the preprint server for biology · 2026Article
- CpG island density predicts CBP/p300 dependency across 3D chromatin clusters.bioRxiv : the preprint server for biology · 2026Article
- Reprogramming lipid metabolism in pediatric cancers.Oncogenesis · 2026Review
- Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young.Molecular cancer therapeutics · 2026Article
- PAX3: A Driver of Normal Development and Disease.Biomolecules · 2026Review
- Review
- Gonystylones A-E, Antiproliferative 5,6-Dihydro-α-pyrones from the PlantJournal of natural products · 2026Article
- Comparative modes of chromatin engagement by PAX::FOXO1 fusions in rhabdomyosarcoma.bioRxiv : the preprint server for biology · 2026Article
- CAR-T cell immunotherapy in rhabdomyosarcoma.Journal of translational medicine · 2026Review
173 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 3 countries.
Berkley E GryderGenetics Branch, NCI, NIH, Bethesda, Maryland.
Marielle E YoheGenetics Branch, NCI, NIH, Bethesda, Maryland.
Hsien-Chao ChouGenetics Branch, NCI, NIH, Bethesda, Maryland.
Xiaohu ZhangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland.
Joana MarquesUniversity Children's Hospital, Zurich, Switzerland.
Marco WachtelUniversity Children's Hospital, Zurich, Switzerland.
Beat SchaeferUniversity Children's Hospital, Zurich, Switzerland.
Nirmalya SenGenetics Branch, NCI, NIH, Bethesda, Maryland.
Young SongGenetics Branch, NCI, NIH, Bethesda, Maryland.
Alberto GualtieriDepartment of Oncohematology, Ospedale Pediatrico Bambino Gesù Research Institute, Rome, Italy.
Silvia PomellaDepartment of Oncohematology, Ospedale Pediatrico Bambino Gesù Research Institute, Rome, Italy.
Rossella RotaDepartment of Oncohematology, Ospedale Pediatrico Bambino Gesù Research Institute, Rome, Italy.
Abigail ClevelandGenetics Branch, NCI, NIH, Bethesda, Maryland.
Xinyu WenGenetics Branch, NCI, NIH, Bethesda, Maryland.
Sivasish SindiriGenetics Branch, NCI, NIH, Bethesda, Maryland.
Jun S WeiGenetics Branch, NCI, NIH, Bethesda, Maryland.
Frederic G BarrLaboratory of Pathology, NCI, NIH, Bethesda, Maryland.
Sudipto DasLaboratory of Proteomics and Analytical Technologies, Advanced Technologies Center, NCI, Frederick, Maryland.
Thorkell AndressonLaboratory of Proteomics and Analytical Technologies, Advanced Technologies Center, NCI, Frederick, Maryland.
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland.
Madhu Lal-NagDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland.
Marc FerrerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland.
Jack F ShernGenetics Branch, NCI, NIH, Bethesda, Maryland.
Keji ZhaoSystems Biology Center, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, Maryland.
Javed KhanGenetics Branch, NCI, NIH, Bethesda, Maryland. khanjav@mail.nih.gov.
National Institutes of Health · USNational Center for Advancing Translational Sciences · USBambino Gesù Children's Hospital · ITUniversity Children's Hospital Zurich · CHAdvanced Systems & Technologies (United States) · USNational Heart Lung and Blood Institute · US
Funding
Genome-wide mapping of histone modificationsZIAHL005801 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ZHAO, KEJI · 2009 to 2025
$24.0MEpigenetic Regulation of Hematopoietic Stem CellsZIAHL006031 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI ZHAO, KEJI · 2009 to 2025
$16.6MTargeting FGFR4, RAS, and PAX3-FOXO1 gene in RhabdomyosarcomaZIABC010999 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$14.0MTrans-NIH RNAi Facility (TNRF)ZICTR000041 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI CHENG, KEN · 2015 to 2025
$9.4MStudies of gene fusions in rhabdomyosarcomaZIABC011387 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BARR, FREDERIC · 2011 to 2025
$9.1MTargeting High-risk Neuroblastoma using high through put siRNA screeningZIABC010806 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$7.8MHTS enabled examination of drug combinationsZIATR000047 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI THOMAS, CRAIG · 2015 to 2025
$7.1MCCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC010806Intramural NIH HHS ZIA HL006031NCI NIH HHS HHSN261200800001E
Abstract
Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and adolescent young adults, driven primarily by the chimeric transcription factor PAX3-FOXO1. The mechanisms by which PAX3-FOXO1 dysregulates chromatin are unknown. We find PAX3-FOXO1 reprograms the
Indexed as
AnimalsBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorChromatinEnhancer Elements, GeneticEpigenesis, GeneticFemaleHumansMaleMiceMyoD ProteinMyogeninN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene Proteins, FusionBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsChromatinMYCN protein, humanMyoD1 myogenic differentiation proteinMyoD ProteinMyogeninMYOG protein, humanN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene Proteins, FusionPaired Box Transcription FactorsPAX3-FOXO1A fusion protein, humanSmall Molecule LibrariesTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.